Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055654 | 0.99 | GSK3A (0.50) | CHRNA3HRH3KCNH2GSK3AGSK3B | |
| SCHEMBL2055626 | 0.97 | CHRNA3 (0.55) | CHRNA3HRH3KCNH2GSK3AGSK3B | |
| SCHEMBL2055607 | 0.97 | CHRNA3 (0.55) | CHRNA3HRH3KCNH2GSK3AGSK3B | |
| SCHEMBL2055877 | 0.97 | GSK3A (0.48) | CHRNA3HRH3KCNH2GSK3AGSK3B | |
| SCHEMBL2055655 | 0.90 | GSK3A (0.52) | CHRNA3GSK3AGSK3B | |
| SCHEMBL2055688 | 0.90 | CHRNA3 (0.52) | CHRNA3KCNH2GSK3AGSK3BCHRNA7 | |
| SCHEMBL2055676 | 0.90 | CHRNA3 (0.52) | CHRNA3KCNH2GSK3AGSK3BCHRNA7 | |
| SCHEMBL2055872 | 0.90 | KCNH2 (0.52) | CHRNA3HRH3KCNH2GSK3AGSK3B | |
| SCHEMBL2055736 | 0.89 | CHRNA3 (0.50) | CHRNA3KCNH2GSK3AGSK3B | |
| SCHEMBL1858599 | 0.89 | CHRNA3 (0.64) | CHRNA3KCNH2GSK3AGSK3BCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | CHRNA3 5/4885HRH3 493/4885KCNH2 1263/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | CHRNA3 5/4885HRH3 384/4885KCNH2 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.